Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5230632 | 0.88 | MET (0.67) | MET | |
| SCHEMBL5230097 | 0.87 | MET (0.66) | METMEN1USP2HPGDMAPK1 | |
| SCHEMBL5231901 | 0.81 | MET (0.69) | METHPGDSMN1; SMN2 | |
| SCHEMBL1060710 | 0.80 | MET (1.00) | MET | |
| SCHEMBL9910361 | 0.74 | MET (1.00) | MET | |
| SCHEMBL5229478 | 0.71 | MET (1.00) | MET | |
| SCHEMBL5229768 | 0.69 | MET (0.78) | MET | |
| SCHEMBL12368487 | 0.68 | MET (1.00) | METMEN1USP2HPGDKMT2A | |
| SCHEMBL5229221 | 0.68 | MET (0.76) | MET | |
| SCHEMBL5228728 | 0.68 | MET (1.00) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1644377-A4 | TRIAZOLOTRIAZINE COMPOUNDS AND USES THEREOF | SUGEN INC (US) | 2007-09-05 | — | — | EP | disclosed |
| US-7122548-B2 | Triazolotriazine compounds and uses thereof | SUGEN, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1644377-A1 | TRIAZOLOTRIAZINE COMPOUNDS AND USES THEREOF | Sugen, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| US-20050075340-A1 | Triazolotriazine compounds and uses thereof | SUGEN, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2005010005-A1 | TRIAZOLOTRIAZINE COMPOUNDS AND USES THEREOF | SUGEN, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075340-A1 | Triazolotriazine compounds and uses thereof | MET, TPMT, RET | MET 1/4885MEN1 45/4885USP2 3873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.